Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carroll talked with Proactive’s Tylah Tully about the company's remarkable achievements in 2024 and its ambitious plans for 2025.
Carroll provided updates on groundbreaking studies involving psilocybin therapies for binge eating disorder, fibromyalgia and irritable bowel syndrome (IBS).
Highlighting this year's milestones, Carroll shared that psilocybin therapies demonstrated remarkable efficacy, including a 100% response rate in reducing binge eating episodes and fibromyalgia pain severity.
The company also advanced its IV-infused psilocybin formulation, offering consistent and controlled dosing, which addresses limitations of oral treatments.
Looking ahead, Carroll outlined three strategic goals for 2025: enhancing intellectual property protections, advancing phase two clinical programs, and developing a commercial-grade formulation for phase three trials.
These efforts reflect Tryptamine's dedication to pushing the boundaries of psychedelic-based therapeutics.